{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:04:53Z","timestamp":1780337093084,"version":"3.54.1"},"reference-count":33,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA11810041"],"award-info":[{"award-number":["HDTRA11810041"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Alphaviruses, belonging to the Togaviridae family, and bunyaviruses, belonging to the Paramyxoviridae family, are globally distributed and lack FDA-approved vaccines and therapeutics. The alphaviruses Venezuelan equine encephalitis virus (VEEV) and eastern equine encephalitis virus (EEEV) are known to cause severe encephalitis, whereas Sindbis virus (SINV) causes arthralgia potentially persisting for years after initial infection. The bunyavirus Rift Valley Fever virus (RVFV) can lead to blindness, liver failure, and hemorrhagic fever. Brilacidin, a small molecule that was designed de novo based on naturally occurring host defensins, was investigated for its antiviral activity against these viruses in human small airway epithelial cells (HSAECs) and African green monkey kidney cells (Veros). This testing was further expanded into a non-enveloped Echovirus, a Picornavirus, to further demonstrate brilacidin\u2019s effect on early steps of the viral infectious cycle that leads to inhibition of viral load. Brilacidin demonstrated antiviral activity against alphaviruses VEEV TC-83, VEEV TrD, SINV, EEEV, and bunyavirus RVFV. The inhibitory potential of brilacidin against the viruses tested in this study was dependent on the dosing strategy which necessitated compound addition pre- and post-infection, with addition only at the post-infection stage not eliciting a robust inhibitory response. The inhibitory activity of brilacidin was only modest in the context of the non-enveloped Picornavirus Echovirus, suggesting brilacidin may be less potent against non-enveloped viruses.<\/jats:p>","DOI":"10.3390\/microorganisms12010054","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T09:56:27Z","timestamp":1703757387000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brilacidin as a Broad-Spectrum Inhibitor of Enveloped, Acutely Infectious Viruses"],"prefix":"10.3390","volume":"12","author":[{"given":"Carol A.","family":"Anderson","sequence":"first","affiliation":[{"name":"Center for Infectious Disease Research, School of Systems Biology, George Mason University, Manassas, VA 20110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Barrera","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research, School of Systems Biology, George Mason University, Manassas, VA 20110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2678-6481","authenticated-orcid":false,"given":"Niloufar A.","family":"Boghdeh","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research, School of Systems Biology, George Mason University, Manassas, VA 20110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miata","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research, School of Systems Biology, George Mason University, Manassas, VA 20110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-2502","authenticated-orcid":false,"given":"Farhang","family":"Alem","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research, School of Systems Biology, George Mason University, Manassas, VA 20110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarthi","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Research, School of Systems Biology, George Mason University, Manassas, VA 20110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Brown, R.S., Wan, J.J., and Kielian, M. (2018). The Alphavirus Exit Pathway: What We Know and What We Wish We Knew. Viruses, 10.","DOI":"10.3390\/v10020089"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","article-title":"Venezuelan equine encephalitis","volume":"49","author":"Weaver","year":"2004","journal-title":"Annu. Rev. Entomol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ronca, S.E., Dineley, K.T., and Paessler, S. (2016). Neurological Sequelae Resulting from Encephalitic Alphavirus Infection. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.00959"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: Gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2796.2004.01413.x","article-title":"Sindbis viruses and other alphaviruses as cause of human arthritic disease","volume":"256","author":"Laine","year":"2004","journal-title":"J. Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/00365540701586996","article-title":"Arthritis and arthralgia three years after Sindbis virus infection: Clinical follow-up of a cohort of 49 patients","volume":"40","author":"Kurkela","year":"2008","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1128\/JVI.02529-06","article-title":"Viral translation is coupled to transcription in Sindbis virus-infected cells","volume":"81","author":"Sanz","year":"2007","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1743-422X-5-82","article-title":"Rift Valley fever virus structural proteins: Expression, characterization and assembly of recombinant proteins","volume":"5","author":"Liu","year":"2008","journal-title":"Virol. J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lihoradova, O.A., Indran, S.V., Kalveram, B., Lokugamage, N., Head, J.A., Gong, B., Tigabu, B., Juelich, T.L., Freiberg, A.N., and Ikegami, T. (2013). Characterization of Rift Valley Fever Virus MP-12 Strain Encoding NSs of Punta Toro Virus or Sandfly Fever Sicilian Virus. PLOS Neglected Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002181"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cll.2017.01.004","article-title":"Rift Valley Fever","volume":"37","author":"Hartman","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1038\/s41467-020-18251-9","article-title":"Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/pgmj.2005.036608","article-title":"Clinical and diagnostic findings of an echovirus meningitis outbreak in the north west of England","volume":"82","author":"Carrol","year":"2006","journal-title":"Postgrad. Med. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00232-011-9343-0","article-title":"Antimicrobial Peptides: Successes, Challenges and Unanswered Questions","volume":"239","author":"Wimley","year":"2011","journal-title":"J. Membr. Biol."},{"key":"ref_14","first-page":"941","article-title":"Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2","volume":"1864","author":"Nikolaou","year":"2019","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-virology-101416-041734","article-title":"Defensins in Viral Infection and Pathogenesis","volume":"4","author":"Holly","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00109-005-0657-1","article-title":"Human defensins","volume":"83","author":"Schneider","year":"2005","journal-title":"J. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4062\/biomolther.2017.172","article-title":"Towards the Application of Human Defensins as Antivirals","volume":"26","author":"Park","year":"2018","journal-title":"Biomol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/jmv.27616","article-title":"Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell","volume":"94","author":"Hu","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bakovic, A., Risner, K., Bhalla, N., Alem, F., Chang, T.L., Weston, W.K., Harness, J.A., and Narayanan, A. (2021). Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses, 13.","DOI":"10.3390\/v13020271"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Benedict, A., Bansal, N., Senina, S., Hooper, I., Lundberg, L., de la Fuente, C., Narayanan, A., Gutting, B., and Kehn-Hall, K. (2015). Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.00676"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Amaya, M., Voss, K., Sampey, G., Senina, S., de la Fuente, C., Mueller, C., Calvert, V., Kehn-Hall, K., Carpenter, C., and Kashanchi, F. (2014). The Role of IKK\u03b2 in Venezuelan Equine Encephalitis Virus Infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086745"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Barrera, M.D., Callahan, V., Akhrymuk, I., Bhalla, N., Zhou, W., Campbell, C., Narayanan, A., and Kehn-Hall, K. (2021). Proteomic Discovery of VEEV E2-Host Partner Interactions Identifies GRP78 Inhibitor HA15 as a Potential Therapeutic for Alphavirus Infections. Pathogens, 10.","DOI":"10.3390\/pathogens10030283"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Boghdeh, N.A., McGraw, B., Barrera, M.D., Anderson, C., Baha, H., Risner, K.H., Ogungbe, I.V., Alem, F., and Narayanan, A. (2023). Inhibitors of the Ubiquitin-Mediated Signaling Pathway Exhibit Broad-Spectrum Antiviral Activities against New World Alphaviruses. Viruses, 15.","DOI":"10.3390\/v15030655"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.1128\/JVI.72.9.7349-7356.1998","article-title":"Binding of Sindbis virus to cell surface heparan sulfate","volume":"72","author":"Byrnes","year":"1998","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.chom.2007.12.001","article-title":"Mechanism of adenovirus neutralization by Human alpha-defensins","volume":"3","author":"Smith","year":"2008","journal-title":"Cell Host Microbe"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Smith, J.G., Silvestry, M., Lindert, S., Lu, W., Nemerow, G.R., and Stewart, P.L. (2010). Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000959"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.antiviral.2019.02.002","article-title":"Human cathelicidin peptide LL-37 as a therapeutic antiviral targeting Venezuelan equine encephalitis virus infections","volume":"164","author":"Ahmed","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_28","first-page":"11","article-title":"A price index for biomedical research and development","volume":"104","author":"Holloway","year":"1989","journal-title":"Public Health Rep."},{"key":"ref_29","unstructured":"(2014, December 04). Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02052388?term=brilacidin&rank=2."},{"key":"ref_30","unstructured":"(2017, December 04). Study of the Effects of Brilacidin Oral Rinse on Radiation-Induced Oral Mucositis in Patients with Head and Neck Cancer (Brilacidin), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02324335?term=brilacidin&rank=1."},{"key":"ref_31","unstructured":"(2020, December 04). A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04240223?term=brilacidin&rank=4."},{"key":"ref_32","unstructured":"(2023, December 08). Brilacidin. Available online: https:\/\/www.ipharminc.com\/brilacidin-1."},{"key":"ref_33","unstructured":"(2021, December 04). A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants with COVID-19, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04784897?term=brilacidin&rank=3."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/1\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:43:06Z","timestamp":1760132586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/1\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["microorganisms12010054"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms12010054","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}